drugset
drugset / Trial / NCT06643728

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

NCT06643728 ↗

Phase 2 Active not recruiting 252 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.

Timeline

Start
2024-10-21
Primary completion
2026-01-16
Completion
2027-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bimagrumab Monoclonal antibody — Subcutaneous
Subject Tirzepatide Peptide — Subcutaneous

Indications

obesity disorder